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Reply to Chinello and Petrosillo
The interest and comments expressed by Chinello and Petrosillo [1] regarding our recent article about antimicrobial-associated QT interval prolongation are greatly appreciated. Because of space constraints, we omitted any discussion regarding antivirals in our article [2] . We would like to echo the concerns raised in the letter by Chinello and Petrosillo [1] , chief among them to emphasize the awareness of QT and metabolic liability of antiretroviral therapy among practicing clinicians involved in the care of HIV-infected patients [3] . Chinello and Petrosillo [1] mention that there is a high magnitude of patients receiving antiretroviral drugs, some of which have QT liability and/or metabolic liability (table 1) ; HIV infection may predispose patients to QT interval prolongation; and finally, a plethora of drugs are now identified to carry QT liability, many of which are likely to be administered to patients with HIV. What makes the aforementioned findings clinically important is the fact that these drugs collide to create "multiple hits" to an individual's repolarization reserve, potentially delaying ventricular repolarization, and if this occurs in great enough magnitude, the patient becomes susceptible to torsades de pointes. "Therapeutic complexity" is a term that defines the treatment of HIV infection today. A recent study reported that HIV-infected patients received a mean (‫ע‬SD) of concurrent medications (the 15.7 ‫ע‬ 7.7 peak end of the range was 39 drugs) [4] . Although combination therapy constitutes the backbone of an effective antiretroviral therapy regimen, the challenge becomes making polypharmaceutical treatment of HIV-infected patients "safer."
Of the currently available antiretroviral agents, QT liability has not been clearly and comparatively delineated for most drugs. With the exception of efavirenz, nonnucleoside reverse-transcriptase inhibitors and nucleoside reverse-transcriptase inhibitors have not raised concerns of QT interval prolongation to date. Conversely, small signals of QT interval prolongation have been observed for some of the currently available protease inhibitors [5, 6] . Atazanavir did not demonstrate an effect on the corrected QT (QTc) interval or on QT dispersion in 1 study [6] , but it did impact the PR interval (which has been identified in other studies). However, signals of atazanavir's proclivity to delay ventricular repolarization were evident during clinical development [7] , and a recent report of its association with torsades de pointes exists (confirmed by rechallenge with subsequent QTc interval prolongation to 571 msec) [8] . The impact of some protease inhibitors on the human ether-a-go-go-related gene (hERG) blockade has been published, demonstrating that protease inhibitors possess some affinity toward the rapid component of the delayed rectifier potassium current, which mechanistically explains most cases of drug-induced torsades de pointes [5] .
Considering the fact that nonnucleoside reverse-transcriptase inhibitors and protease inhibitors are also cytochrome P450 (CYP) substrates and notorious inhibitors of CYP3A4 (table 1) , the additional risk of interactions with numerous drugs warrants significant attention. For example, concurrent administration of drugs that inhibit CYP3A4 activity (e.g., macrolides and azole antifungals) with efavirenz or protease inhibitors, which are CYP3A4 substrates with QT liability, may lead to increased exposure of the latter, to QT in- terval prolongation, and possibly, to torsades de pointes. Furthermore, because nonnucleoside reverse-transcriptase inhibitors and protease inhibitors are potent inhibitors of CYP3A4, they have the potential to reduce the clearance of other coadministered agents with intrinsic QT liability, including the list of commonly used drugs mentioned by Chinello and Petrosillo [1] , perhaps the most significant among them being methadone. Of the antiretroviral agents, only the nucleoside reverse-transcriptase inhibitors appear to be devoid of both QT and metabolic liability (table 1) . More data are needed to establish the association between HIV infection and its effect on the QT interval. In addition, robust comparative assessments of QT liability (e.g., hERG studies, animal models to determine drug effects on the QT interval, safety data from clinical trials using continuous electrocardiographic monitoring methods and outlier assessments, and postmarketing adverse event reporting database evaluations) are needed for existing antiretroviral agents. Knowledge of intrinsic QT liability superimposed on well-described host factors that increase a patient's susceptibility to QT interval prolongation, as well as knowledge of CYP metabolism characteristics of drugs under consideration for addition to the patient's antiretroviral therapy regimen, would provide a thorough risk-versus-benefit assessment. Although some individual "hits" to the repolarization reserve may be impossible to avoid, it is possible to minimize their cumulative number, thus making polypharmacy "safer" from a cardiac toxicity perspective.
Extended-Spectrum b-Lactamases, Food, and Cephalosporin Use in Food Animals
To the Editor-Infections caused by Escherichia coli and other gram-negative bacteria are very common. A large proportion of these strains are resistant to oral antibiotics. When resistance to injectable antibiotics, such as third-and fourthgeneration cephalosporins, is also present, the patient can experience grave consequences, because injectable antibiotics are often the last line of defense and are critically important in treating many lifethreatening infections, including bacteremia and meningitis. Thus, the unexpected and increasing appearance of extended-spectrum b-lactamases (ESBLs) among community isolates of E. coli and other bacteria, as outlined in 2 articles recently published in Clinical Infectious Diseases [1, 2] , is of major concern.
However, these articles do not mention that food might be a very important vehicle in the spread of these drug-resistant bacteria, as was again highlighted by a recent study from Spain [3] . The use of third-and fourth-generation cephalosporins in food animals results in the development of bacteria carrying ESBLs. This involves not only food-associated pathogens, such as Salmonella species [4] , but also E. coli. These drug-resistant bacteria then spread to people via food and other routes (e.g., ground water). This is occurring around the world [4] [5] [6] [7] . These drugresistant bacteria and their genes (including CTX-M and CMY b-lactamases) are now widespread.
Antibiotic-resistant strains of E. coli probably spread via food much more commonly than we currently appreciate [8] . If drug-resistant bacteria are widespread in the intestinal tracts of people in the community, the treatment of these people with antibiotics will frequently result in the amplification of drug-resistant bacteria (and in the transfer of the genes encoding drug resistance into other bacteria). If such individuals are hospitalized for an incidental reason (e.g., biliary disease or trauma), then these bacteria can spread to other patients, especially if infection-control practices are not universally followed.
Worldwide, third-generation cephalosporins, such as ceftiofur, are widely used in many different food animals, because there are often only minimal restrictions in place on its use. Indeed, in the United States in 2001, ceftiofur was injected into the eggs of meat chickens just before hatching in 21 (78%) of 27 hatcheries (the hatcheries studied produced 1500 million chickens per year; this US Food and Drug Administration data was obtained under a Freedom of Information search). In Australia, attempts to limit the widespread use of ceftiofur by placing "label restraints" on its use have been ignored by the agriculture regulatory agency. The use of thirdand fourth-generation cephalosporins in most developing countries is even more widespread, because there are usually even fewer controls in place.
Recently, a fourth-generation cephalosporin (cefquinome) was approved for use by the European Union, and it is likely to also be approved soon by the US Food and Drug Administration, without any label restrictions. This will mean that it can be used in any food animal for almost any indication. Restrictions, such as requiring a prescription to dispense the drug, seem to make little difference in effective control, as is evidenced by the widespread use of fluoroquinolones and the resultant drug resistance that recently lead the US Food and Drug Administration to finally withdraw approval for their use in poultry (but only after a long and drawn-out legal battle with the manufacturer) [9] . Better "late than never," but why did we have to wait for drug resistance to be so widespread before taking action? How could we possibly have expected that the use of "critical" antibiotics, such as fluoroquinolones or third-generation cephalosporins, would not have resulted in the development of drug resistance?
Unlabeled but high levels of broadspectrum cephalosporins (e.g., ceftiofur) [10] are allowed in some foods (maximum residual level, 6 mg per kg). These high levels mean that ceftiofur is used instead of narrower-spectrum antibiotics, because the much higher maximum residual levels of ceftiofur result in a much shorter period of withholding the treated animal from slaughter than would be the case with many other antibiotics. These high levels will also be an allergic risk to some people.
This all seems to be a recipe for disaster. We have already seen early warning signs that the use of ESBLs is starting to get out of control [1] [2] [3] [4] [5] [6] [7] . Surely, now is the time to act. The World Health Organization has defined third-and fourth-generation cephalosporins as being "critically important" for use in people [11] . Clearly, these antibiotics should not be used in food animals at all (or their use should be much
